psychoneuro, Inhaltsverzeichnis psychoneuro 2006; 32(12): 572-573DOI: 10.1055/s-2006-958821 Blickpunkt © Georg Thieme Verlag KG Stuttgart · New York Doppeldiagnose: Nutzen unter Risperidon in Depotform - Verbesserung von Symptomatik und Compliance Artikel empfehlen Abstract Volltext Referenzen Quellen 01 Glazer VM . et al . Depot neuroleptic therapy: an underutilized treatment opinion. J Clin Psychiatry. 1992; 53 426-33 02 Ziedonis DM . et al . Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model. Schizophr Bull. 1997; 23 229-38 03 Rubio G . et al . Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006; 51(8) 531-9 04 Regier DA . et al . Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area Study. JAMA. 1990; 264 273-9 05 Linszen DH . et al . Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994; 51 273-9 06 Dixon L . Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999; Suppl 35 93-100 07 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde DGPPN (Hrsg.). S3-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 - Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag, 2005.
